This is a working overview of GABA-A receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-15. Anything still debated is marked as such rather than presented as settled.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
| Property | Value | Notes |
|---|---|---|
| Dry storage temperature | -20 C or below | Sealed, desiccated, protected from light |
| Solution stability | Hours to days at 2-8 C | Depends on buffer and microbial load |
| Preferred pH range | Near neutral to slightly acidic | Alkaline pH accelerates hydrolysis |
| Main degradation routes | Hydrolysis and deamidation | No cysteine or methionine in sequence |
| Identity confirmation | Electrospray mass spectrometry | Observed mass compared with 751.9 Da |
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
== Clinical significance == It has been shown that low levels of glutathione peroxidase as measured in the serum may be a contributing factor to vitiligo. Lower plasma glutathione peroxide levels were also observed in patients with type 2 diabetes with macroalbuminuria and this was correlated to the stage of diabetic nephropathy. In one study, the activity of glutathione peroxidase along with other antioxidant enzymes such as superoxide dismutase and catalase was not associated with coronary heart disease risk in women. Glutathione peroxidase activity was found to be much lower in patients with relapsing-remitting multiple sclerosis. One study has suggested that glutathione peroxidase and superoxide dismutase polymorphisms play a role in the development of celiac disease. The activity of this enzyme has been reported to be decreased in case of copper deficiency in the liver and plasma.
=== Transthyretin-related hereditary amyloidosis === The FDA granted Patisiran (Onpattro) orphan drug status and breakthrough therapy designation due to its novel mechanism involving RNA therapy to block the production of an abnormal form of transthyretin. Patisiran received full FDA approval in 2018 and its RNA lipid nanoparticle drug delivery system was later used in the Pfizer–BioNTech COVID-19 vaccine and Moderna RNA vaccines.
== Organization and administration == The University of Arizona, like its sister institutions Arizona State University and Northern Arizona University, is governed by the Arizona Board of Regents or the ABOR, a 12-member body. Eight volunteer members are appointed by the Governor to staggered eight-year terms; two students serve on the board for two-year appointments, with the first year being a nonvoting apprentice year. The Governor and the Superintendent of Public Instruction serve as voting ex-officio members. The ABOR provides "policy guidance" and oversight to the three major degree-granting universities, as provided for by Title 15 of the Arizona Revised Statutes. Suresh Garimella was named the 23rd president of the U of A on August 9, 2024. Previously, he was the president of the University of Vermont from 2019 to 2024. Garimella has also previously served as the Executive Vice President for Research and Partnerships, a Chief Global Affairs Officer, and was recognized as a Goodson Distinguished Professor of Mechanical Engineering at Purdue University. Garimella replaced Robert C. Robbins, MD. He was named as the lone finalist to succeed as president after Robbins announced his plans to step down at the end of his current contract, or before if a suitable successor was identified, during an ABOR meeting on April 2, 2024.
Sources: en.wikipedia.org
Traditional ayahuasca brews are usually made with Banisteriopsis caapi as an MAOI, while dimethyltryptamine sources and other admixtures vary from region to region. There are several varieties of caapi, often known as different "colors", with varying effects, potencies, and uses. DMT admixtures:
The king cobra's skin is olive green with black and white bands on the trunk that converge to the head. The head is covered by 15 drab-coloured and black-edged shields (large scales consistently present between individuals). The muzzle is rounded, and the tongue black. It has two fangs and 3–5 maxillary teeth in the upper jaw, and two rows of teeth in the lower jaw. The nostrils are between two shields. The large eyes have a golden iris and round pupils. Its hood is oval shaped and covered with olive green smooth scales and two black spots between the two lowest scales. Its cylindrical tail is yellowish green above and marked with black. It has a pair of large occipital scales on top of the head, 17 to 19 rows of smooth oblique scales on the neck, and 15 rows on the body. Juveniles are black with chevron shaped white, yellow or buff bars that point towards the head. Adult king cobras are 3.18 to 4 m (10.4 to 13.1 ft) long. The longest known individual measured 5.85 m (19.2 ft). Ventral scales are uniformly oval shaped. Dorsal scales are placed in an oblique arrangement. The king cobra is sexually dimorphic, with males being larger and paler in particular during the breeding season. Males captured in Kerala measured up to 3.75 m (12.3 ft) and weighed up to 10 kg (22 lb). Females captured had a maximum length of 2.75 m (9 ft 0 in) and a weight of 5 kg (11 lb). The largest known king cobra was 5.59 m (18 ft 4 in) long and captured in Thailand. It differs from other cobra species by size and hood. It is larger, has a narrower and longer stripe on the neck.
=== Amateur === Lisa has been weight training since 2003 and has been conditioning for competitive entry since 2008. She first really got into bodybuilding in 2006 while she was living in Japan while she was teaching English. Her boyfriend at the time was a Japanese bodybuilding champion and she started reading up on bodybuilding, such as Negrita Jayde, and started training with weights. In 2007, after she got married, she went to see the 2007 Ms. Olympia competition for their honeymoon and was impressed when she saw female bodybuilders for the first time. Former UK junior champion Lewis Breed oversees her training and pre-contest preparation for bodybuilding. She competed in her debut competition at the 2009 NABBA England, placing second place behind Jennie Ellam. She then competed at the 2009 NABBA Universe achieving second place to Larissa Cunha. Her best win was first place at the UKBFF British Championships, where she won the Ladies Physique class. On 19 March 2014, she announced that she had been awarded her IFBB pro card and can now compete as a pro.
=== December 2005 === John Pace, human rights chief for the United Nations Assistance Mission in Iraq (UNAMI), told Reuters that there were an estimated 14,000 people being held in prison in Iraq contrary to UN Resolution 1546, according to which the US government claims legal permission to occupy Iraq. In a December 5, 2005, interview, Pace said,
Sources: en.wikipedia.org
cassette A pre-existing nucleic acid sequence or construct, especially a DNA vector with an annotated sequence and precisely positioned regulatory elements, into which one or more fragments can be readily inserted or recombined by various genetic engineering methods. Recombinant plasmid vectors containing reliable promoters, origins of replication, and antibiotic resistance genes are commercially manufactured as cassettes to allow scientists to easily swap genes of interest into and out of an active "slot" or locus within the plasmid. See also multiple cloning site.
Proteins with GO terms related to polysaccharide binding and processing were enriched for serine and threonine in their LCRs. Proteins with GO terms related to RNA binding and processing were enriched for arginine in their LCRs. Proteins with GO terms related to DNA binding and processing were especially enriched for lysine, but also for glycine, tyrosine, phenylalanine and glutamine in their LCRs. Proteins with GO terms related to metal binding and more specifically to cobalt or nickel-binding were enriched mostly for histidine but also for aspartate in their LCRs. Proteins with GO terms related to protein folding were enriched for glycine, methionine and phenylalanine in their LCRs. Based on the above observations and analyses, a Neural Network webserver named LCR-hound has been developed to predict LCRs and their function.
== Types of warfare == Cyber warfare can present a multitude of threats towards a nation. At the most basic level, cyber attacks can be used to support traditional warfare. For example, tampering with the operation of air defenses via cyber means in order to facilitate an air attack. Aside from these "hard" threats, cyber warfare can also contribute towards "soft" threats such as espionage and propaganda. Eugene Kaspersky, founder of Kaspersky Lab, equates large-scale cyber weapons, such as Flame and NetTraveler which his company discovered, to biological weapons, claiming that in an interconnected world, they have the potential to be equally destructive.
Sources: en.wikipedia.org
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.
Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.
Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.